Full-Time

Cold Chain Pharmacy Distribution Engineer

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Supply Chain Management
Six Sigma
Inventory Management
SAP Products
Visio
Excel/Numbers/Sheets

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Minimum of 7 years of operations process experience, ideally in the pharmaceutical distribution industry.
  • Highly proactive with the ability to work independently.
  • Highly organized with a strong ability to prioritize tasks and deliverables across a portfolio.
  • Excellent communication skills, including experience presenting in front of leadership.
  • Fluent English language skills (both verbal and written).
  • Ability to travel domestically and internationally up to 25%.
  • Five plus years of BU or BU-facing experience, with sensitivity and commitment to business problem solving specifically in pharma, specialty pharma, and supply chain management.
  • Demonstrated experience and ability to use soft skills successfully.
  • Demonstrated experience in leading a cross-functional, global project teams.
  • Experience in logistics and distribution environments, third party logistics and cold chain.
  • Pharmaceutical regulatory compliance, e.g., FDA, DSCSA, QMS, beneficial.
  • Experience working with or leading IT teams in developing SAP-centric solutions beneficial.
  • Minimum bachelor’s degree in business, logistics, engineering, or similar, or an equivalent blend of work and certification experience
  • Lean Six Sigma Green Belt or Black Belt preferred.
  • Intermediate user of LucidCharts, Box, Zoom, and Microsoft Visio, PowerPoint, Project, Excel, or similar
Responsibilities
  • Lead logistics workstream for new pharmaceutical product introductions from later-stage development through commercialization, including establishing the logistics network (e.g., 3PL, specialty distributors, wholesalers).
  • Define the end-to-end processes including inventory management, order flow, EDI/IT systems.
  • Execute Fluorescence Imaging and Global Logistics projects within the approved budget, timeline and scope.
  • Create process flow maps to help team partners and leaders gain a deeper understanding of process options.
  • Assist in the management of day-to-day relationships with 3PL providers, specialty distributors, and wholesalers with Fluorescence Imaging organization.
  • Develop and maintain project management infrastructure supporting project collaboration, communications, and delivery (e.g., Smartsheet, Box folders, project artifacts).
  • Identify and schedule project deliverables, milestones, required activities and tasks.
  • Assist in the creation of the Project Charter, execute and monitor to the Project Charter.
  • Establish work plan and staffing for project activities, iterations or phases, and arrange for recruitment or assignment of project personnel.
  • Implement project communication plan.
  • Develop and execute logistics launch plans, including timelines, risks, and mitigation strategies.
  • Ensure that project goals are accomplished and are in line with business objectives and success metrics.
  • Direct and coordinate activities of project personnel to ensure that the project progresses on scope, on schedule and within budget.
  • Present recommendations or ask for specific support to “go to green” of steering committees and leadership.
  • Collaborate with upstream and downstream partners to understand process pain points and drive improvements impacting cross-functional KPIs.
  • Present project updates, findings, and detailed, prioritized recommendations to sponsors and key stakeholders in various formats (e.g., Smartsheet dashboards, written reports, steering committees).
  • Collaborate with Global Process Owners to implement system and process improvements ensuring alignment and consistency for the Specialty program.
Desired Qualifications
  • Program or Product ownership
  • Familiarity with ISO13485:2016 and MDSAP
  • APICS certification

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $2.89 billion, up 19%, with 70% gross margin.
  • Europe direct operations started March 2, 2026, adding Italy, Spain, Portugal, and Malta.
  • Ion procedures grew 36% in Q2 2026, expanding beyond da Vinci dependence.

What critics are saying

  • FDA posted a Class II da Vinci 5 recall on February 18, 2026.
  • Surgical Instrument Service and the FTC pressed Ninth Circuit antitrust claims on June 25, 2026.
  • US da Vinci growth slowed to 12% in Q2 2026, threatening premium pricing.

What makes Intuitive Surgical unique

  • Da Vinci 5 cleared for cardiac procedures on January 26, 2026.
  • Intuitive owns 11,710 da Vinci and 1,096 Ion systems, creating switching costs.
  • July 23, 2026 AI platform leverages 20 million procedures, unmatched surgical data scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

Yahoo Finance
Jul 29th, 2026
Intuitive Surgical stock falls 27% despite 31% operating margin and strong da Vinci system sales

Intuitive Surgical's stock has fallen 27% over the past twelve months, now trading 41% below its two-year high. The robotic surgery pioneer trades at 40.8 times earnings, the highest valuation in its sector. The company maintains a 31% operating margin, outpacing Johnson & Johnson's 27% and Medtronic's 18.8%. Revenue grew 21% over the last twelve months. The firm placed 468 da Vinci systems in the most recent quarter, an 18% increase year-over-year, driven by demand for its new da Vinci 5 platform. However, US procedure growth slowed to 12%, compared to 15% worldwide growth. Management attributed the slowdown to changes in patient coverage and premium dynamics causing treatment deferrals.

Yahoo Finance
Jul 20th, 2026
Intuitive Surgical shares drop 14% despite $2.89B revenue as US procedure growth slows to 12%

Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 19% year-on-year and beating Wall Street estimates. Despite this, shares fell 14.1% to a new 52-week low on Friday. The drop followed concerns about slowing US procedure volumes. Whilst global procedures grew 16%, growth for da Vinci systems in the critical US market moderated to 12%. Management noted that changes in patient coverage may be affecting demand for elective procedures. Paradoxically, capital equipment sales remained strong, with 468 da Vinci systems placed in the quarter, up 18% year-on-year. US placements jumped 24%, driven by the new da Vinci 5 platform. Management also detailed plans for an extended use programme launching in 2027, aimed at reducing costs but potentially impacting high-margin recurring revenue.

Yahoo Finance
Jul 16th, 2026
Intuitive Surgical Q2 revenue climbs 19% to $2.89B as procedures grow 16% globally

Intuitive Surgical reported strong Q2 results, with revenue up 19% year-over-year to $2.89 billion and non-GAAP earnings per share rising 28% to $2.80. Recurring revenue accounted for 85% of total sales. Total procedures increased 16%, driven by 15% growth in da Vinci procedures and 36% growth in Ion procedures. Whilst US growth slowed, international da Vinci procedures rose 20%, expanding across Europe and Asia. The company maintained its 2026 procedure outlook, keeping da Vinci procedure growth guidance at 13.5% to 15.5% whilst raising its non-GAAP gross margin forecast to 68% to 69%. Management highlighted continued demand for newer platforms including da Vinci 5, SP and Ion. The installed base grew to nearly 13,000 systems worldwide.

Yahoo Finance
Jul 16th, 2026
Intuitive Surgical beats Q2 revenue estimates with $2.89B but shares fall on surgery volume concerns

Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 18.5% year on year and beating Wall Street estimates of $2.82 billion. The medical technology company's non-GAAP profit of $2.80 per share exceeded analyst expectations by 11.9%. Despite the strong results, the stock declined. The drop was attributed to recent declines in overall surgery volumes reported by major healthcare providers and a Class II recall of certain da Vinci surgical components. Operating margin improved to 33.6%, up from 30.5% in the same quarter last year. Analysts expect revenue to grow 12.5% over the next 12 months, representing a deceleration from recent growth rates. The company has demonstrated solid long-term performance, with 16.4% annualised revenue growth over the past five years.